High-dose oral methylprednisolone for the treatment of multiple sclerosis relapses: cost-minimisation analysis and patient’s satisfaction

ObjectiveTo study the use of high-dose oral methylprednisolone compounded formulation and intravenous methylprednisolone for the treatment of multiple sclerosis relapses. To compare both routes of methylprednisolone administration related to cost and patient’s satisfaction with the treatment.Methods...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2019-09, Vol.26 (5), p.280-284
Main Authors: Horta-Hernández, Ana María, Esaclera-Izquierdo, Begoña, Yusta-Izquierdo, Antonio, Martín-Alcalde, Eva, Blanco-Crespo, María, Álvarez-Nonay, Adriana, Torralba, Miguel
Format: Article
Language:English
Subjects:
Age
Chronic illnesses
Cost control
cost-minimization analysis
Demographics
Disease
Drug stores
Hospitals
Meta-analysis
Multiple sclerosis
Normal distribution
Original
Original article
Patient satisfaction
patient’s satisfaction
Pharmacists
Questionnaires
relapse
Steroids
treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectiveTo study the use of high-dose oral methylprednisolone compounded formulation and intravenous methylprednisolone for the treatment of multiple sclerosis relapses. To compare both routes of methylprednisolone administration related to cost and patient’s satisfaction with the treatment.MethodsA retrospective cohort observational study was performed from January 2012 to December 2016. All multiple sclerosis relapses treated with high-dose oral methylprednisolone compounded formulation or intravenous methylprednisolone were studied. Patient’s acceptance grade of the treatment was analysed with a survey based on the Treatment Satisfaction Questionnaire for Medication. A cost-minimisation analysis using real world data from our hospital was performed to compare the high-dose oral methylprednisolone formulation and intravenous administration.Results92 patients were included (88% had recurrent remitting multiple sclerosis). Median Expanded Disability Status Scale score was 2 (IRC: 1–3.5). 162 relapses were treated: 77 with intravenous methylprednisolone and 85 with high-dose oral methylprednisolone formulation. The most frequent prescriptions were 1000 mg intravenous methylprednisolone and 1250 mg oral methylprednisolone during 4 days. Recovery from relapse was achieved in 91% of patients in the intravenous group and 93% in the oral group. The survey revealed that 79% of patients preferred the oral route because of convenience (P
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2018-001499